Resmed (RMD) Gains from Investment Securities (2010 - 2026)

Resmed has reported Gains from Investment Securities for 17 years, with the latest figure at $71.7 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities rose 370.3% year-over-year to $71.7 million; the trailing twelve-month figure through Mar 2026 stood at $86.9 million (up 321.36% YoY), and the FY2025 full-year result was $3.6 million, up 297.19% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $71.7 million, down from $208.7 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $208.7 million in Q4 2025, with the low at -$330.6 million in Q1 2022.
• Historically, Gains from Investment Securities has averaged $6.4 million across 5 years, with a median of $61.8 million in 2024.
• Annual changes were most pronounced in 2023 — Gains from Investment Securities surged 129983.05% — and 2024, when it slumped 432.53%.
• Resmed's Gains from Investment Securities stood at $29.7 million in 2022, then jumped by 226.05% to $96.7 million in 2023, then climbed by 22.71% to $118.6 million in 2024, then surged by 75.9% to $208.7 million in 2025, then sank by 65.66% to $71.7 million in 2026.
• The last three Gains from Investment Securities figures came in at $71.7 million (Q1 2026), $208.7 million (Q4 2025), and $719000.0 (Q3 2025), per Business Quant data.